Statins reduce fatal prostate cancer risk
Statin use appears to reduce the risk of fatal prostate cancer according to a study published in Clinical Cancer Research.
Researchers from Queen’s University, Belfast, prospectively examined statin use and fatal prostate cancer risk in 44 126 men who were cancer-free in 1990 and were followed for prostate cancer incidence and statin use until 2014.
6305 prostate cancers were diagnosed during 24 years of follow-up and 13% were fatal (metastatic at diagnosis or metastatic/fatal during follow-up). Current statin use reduced the risk of lethal prostate cancer relative to never/past use (hazard ratio [HR], 0.76; 95% confidence interval, 0.60–0.96). There was a strong negative association for cancers lacking the tumor suppressor gene PTEN (HR, 0.40; 95%, CI, 0.19–0.87) but not for cancers with the PTEN gene (HR, 1.18; 95% CI, 0.95–1.48).
Statin use has previously been linked to less aggressive prostate cancers but this is the first time it has been linked to fatal disease and with a specific genetic cancer profile that helps identify a putative mechanism.